Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

antee that SOM230 will be submitted or approved for sale in any market, or for any particular indication, or at any particular time. Nor can there be any guarantee that SOM230 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding SOM230 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, the Novartis Group offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. The Novartis Group is the only company with
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug ... treatment of Major Depressive Disorder in adult patients who have ... the current episode. TMS is a non-invasive technique for stimulating ... patients suffering from Major Depressive Disorder. The procedure has been ...
(Date:8/28/2015)... , August 28, 2015 The report "Eubiotics ... (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ( ... Asia-Pacific , and Rest of the World) - ... global market for Eubiotics was valued at USD 4.62 Billion ... by 2020, at a CAGR of 7.4% from 2015 to ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... SPRING, Md., July 13, 2011 The U.S. Food ... warning health care providers and patients that surgical placement ... prolapse may expose patients to greater risk than other ... The safety communication also says that with ...
... Corporation,s Orthopaedics division has reached a mutual agreement with ... of the Cormet Hip Resurfacing System. Stryker will no ... "Distribution of a hip resurfacing device no longer ... Vice President, Global Hip Reconstruction Marketing, Stryker Orthopaedics. Stryker,s ...
Cached Medicine Technology:FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 2FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 3FDA: Surgical Placement of Mesh to Repair Pelvic Organ Prolapse Poses Risks 4Stryker Ends Distribution Agreement With Corin PLC 2
(Date:8/29/2015)... ... ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy and Prevention ... educational program titled “Asbestos and Your Health.” , The two and one half hour ... at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. , This ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder ... mission is to increase acceptance of the chiropractic field in the military. All too ... them. Although Chiropractic was made available to the VA program over a decade ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... AZ (PRWEB) , ... August 29, 2015 , ... ... reinvent higher learning and the student experience as part of the EDUCAUSE - Next ... Gates Foundation . , This is the third Breakthrough Models Incubator hosted ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department ... qualified for the position they are applying for, they are unable to pass the ... are considering altering drug testing policies in order to be able to hire long-term, ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... from Netherlands said that men with increased levels of sex ... dementia. // ,This hormone is present at a ... results are published in the Annals of Neurology. Dr. Mirjam ... the study among 2974 older men for a period of ...
... new review of 70 studies shows that alternative and ... easing symptoms associated with menopause.// The review article is ... Internal Medicine, one of the JAMA/Archives journals. ... next decade, and many of them will experience hot ...
... in 2500 people suffer from hereditary Charcot-Marie-Tooth (CMT) disease. ... unclear. However researchers from the// Flanders Interuniversity Institute for ... now reported that mutations in mitofusin 2 are the ... also be the basis of a new genetic test. ...
... Louis University geriatricians say that many older adults who ... their problem has no// solution need not fret any ... life, but sleep problems in the elderly are not ... assistant professor of geriatrics at Saint Louis University, and ...
... Ranbaxy Laboratories and Aurobinda Pharma were among some of ... UN Secretary General Kofi Annan // for their ... ,Annan complimented these companies for their efforts ... a meeting with their top executives at United Nations ...
... novel idea of using air waves to propagate AIDS awareness ... concept, pioneered by the Madhya Pradesh State AIDS Control Society ... the radio dealing exclusively with AIDS-related issues. ,"Using ... has two advantages. Firstly, no other media can match the ...
Cached Medicine News:Health News:Alternative Therapies May Not Ease Menopause Symptoms 2Health News:Genetic Mutation Implicated in Charcot-Marie-Tooth Disease 2Health News:Help Near At Hand For Elderly With Disturbed Sleep 2Health News:Madhya Pradesh Uses Radio to Create Awareness About AIDS 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: